Fresh hope for relapsed T-cell acute lymphoblastic leukemia

A global collaboration between Tampere University (Finland), the Massachusetts General Research Institute and the Harvard Stem Cell Institute (both MA, USA) has found a new drug combination that is effective against T-cell acute lymphoblastic leukemia – otherwise known as T-ALL.  T-ALL is a form of ALL (the most common childhood cancer) that has a poor prognosis and develops from early T lineage cells. Relapsed T-ALL, in particular, desperately requires innovative new combination treatments due to the fact that individual drugs tend to rapidly lose their efficacy for leukemia.   The research team from Tampere University previously discovered that the general tyrosine...